ASX Share rice
Sat 15 May 2021 - 02:42:am (Sydney)

MEB Share Price

MEDIBIO LIMITEDMEBHealth Care Equipment & Services

MEB Company Information

Name:

Medibio Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Health Care Technology

GIC Sub Industry:

Health Care Technology

Address:

100 Albert Road Melbourne VIC Australia 3205

Phone:

61 3 9692 7222

Managing Director, CEO & Director:

Mr. Claude Solitario

Joint Company Sec. & Director:

Ms. Melanie Jaye Leydin C.A., B.Bus, CA

Operations & Account Mang.:

Ms. Renee Stanton-Horne

Investor Relations Director:

Ms. Stephanie Ottens

PR Director:

Mr. Josh Purdy

Head of Research:

Dr. Michael Player

Head of Algorithm Devel. Team:

Dr. Matthew Flax

Chief Medical Officer:

Mr. Archie Defillo M.D.

Sr. VP of Corp. Health:

Ms. Jennifer Solitario

Head of Artificial Intelligence:

Mr. Massimiliano Grassi

Company Overview:

Medibio Limited, a health technology company, researches, develops, and commercializes mental health technology to assist in the screening, diagnosing, monitoring, and management of depression and other mental health conditions in Australia and the United States. It offers mental well-being solutions for businesses through corporate health product; and develops products for healthcare provider market. Medibio Limited has a clinical trial agreement with MedBridge Healthcare LLC to support Medibio's sleep analysis of depressive burden (SADB) trial. The company was formerly known as BioProspect Limited and changed its name to Medibio Limited in November 2014. Medibio Limited was incorporated in 1987 and is based in Melbourne, Australia.

MEB Share Price Information

Shares Issued:

1.79B

Market Capitalisation:

$12.54M

Revenue (TTM):

$1.16M

Revenue Per Share (TTM):

$0

Earnings per Share:

$-0.03

Profit Margin:

-1.9096

Operating Margin (TTM):

$-1.73

Return On Assets (TTM):

$-0.08

Return On Equity (TTM):

$-0.17

Quarterly Revenue Growth (YOY):

0.304

Gross Profit(TTM):

$720.58K

Diluted Earnings Per Share (TTM):

$-0.002

MEB CashFlow Statement

CashFlow Date:

2020-06-30

Investments:

$-1,504,948

Change To Liabilities:

$-604,161

Total Cashflow From Investing Activities:

$-1,504,948

Net Borrowings:

$-154,625

Net Income:

$-3,872,404

Total Cash From Operating Activities:

$-3,588,818

Depreciation:

$148.87K

Other Cashflow From Investing Activities:

$36.52K

Change To Account Receivables:

$-17,631

Capital Expenditures:

$1.54M

MEB Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-3,872,400

Net Income:

$-3,872,400

Gross Profit:

$728.14K

Operating Income:

$-3,835,720

Other Operating Expenses:

$1.99M

Interest Expense:

$36.69K

Total Revenue:

$0.93M

Cost Of Revenue:

$204.69K

MEB Balance Sheet

Balance Sheet Date:

2020-06-30

Intangible Assets:

$13M

Total Liabilities:

$1.40M

Total Stockholder Equity:

$12.61M

Total Assets:

$14.01M

Common Stock:

$91.67M

Other Current Assets:

$16.69K

Retained Earnings:

$-84,382,930

Other Assets:

$3.36M

Cash:

$812.50K

Total Current Liabilities:

$1.40M

Property - Plant & Equipment:

$71.44K

Net Tangible Assets:

$2.89M

Total Current Assets:

$861.70K

Net Receivables:

$32.51K

Short-Term Investments:

$13.15M

Accounts Payable:

$1.20M

Non Currrent Assets (Other):

$78.27K

Short-Term Investments:

$13.15

Non Current Liabilities Total:

$0

MEB Share Price History

MEB News

19 Jan, 2021
Medibio Limited (MEB or the Company)(ASX: MEB)(OTCPINK: MDBIF), is pleased to announce that it has received CE Mark approval for its sleep staging software, MEBsleep.